Ticker Sage

Form 4 · MRK

Merck EVP&Pres Richard R. DeLuca reports selling 58,185 shares

Richard R. DeLuca, Merck's EVP&Pres, Merck Animal Heallth, filed a Form 4 on Nov 16, 2026 at 4:19 PM ET reporting transactions on Nov 12, 2026.

The filing reports 58,185 shares in an open-market or private sale (code S) at $148.01, about $8.6 million in total; and 58,185 shares in an exercise or conversion of a derivative security (code M).

The filing does not indicate that the sales were made under a Rule 10b5-1 trading plan.

After these transactions, the filing lists about 112,955 shares held directly.

Reporting person

Transactions as reported

DateCodeSecuritySharesPriceAcquired or disposedHeld afterOwnership
2026-11-12MCommon Stock58,185$77.62Acquired171,140Direct
2026-11-12SCommon Stock58,185$148.01Disposed112,955Direct
2026-11-12MStock Option (Right to Buy) (derivative)58,185Disposed0Direct

Codes: P purchase, S sale, A grant or award, M/X/C exercise or conversion, F shares withheld for taxes or the exercise price, G gift. Prices are as reported; some are weighted averages of several trades.

Source

Merck company file → · More Merck filings

Disclosures

Editor holdings in MRK
The editor holds no position in Merck (MRK). As of Nov 11, 2026.
Last updated
Nov 16, 2026

A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold MRK.